Related Experiment Video
Updated: Jun 12, 2026
08:36
Chitosan/Interfering RNA Nanoparticle Mediated Gene Silencing in Disease Vector Mosquito Larvae
Published on: March 25, 2015
Targeted gene silencing using RGD-labeled chitosan nanoparticles
Hee Dong Han1, Lingegowda S Mangala, Jeong Won Lee
1Department of Gynecologic Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
Summary
Researchers developed a novel Arg-Gly-Asp (RGD) peptide-labeled chitosan nanoparticle (RGD-CH-NP) for targeted delivery of short interfering RNA (siRNA) to tumors, demonstrating significant antitumor efficacy.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Targeted delivery of therapeutic agents like short interfering RNA (siRNA) is crucial for effective cancer treatment.
- Chitosan nanoparticles offer a biocompatible platform for drug delivery.
- Overcoming limitations of conventional therapies requires novel delivery systems.
Purpose of the Study:
- To develop an Arg-Gly-Asp (RGD) peptide-labeled chitosan nanoparticle (RGD-CH-NP) system.
- To utilize RGD-CH-NP for targeted delivery of siRNA to tumors.
- To evaluate the antitumor efficacy of this novel delivery system.
Main Methods:
- Conjugation of RGD peptide to chitosan via thiolation, confirmed by proton-NMR (¹H-NMR).
- Assessment of RGD-CH-NP binding to αvβ3 integrin using flow cytometry and fluorescence microscopy.
- Evaluation of antitumor efficacy in orthotopic mouse models of ovarian carcinoma.
Main Results:
- RGD-CH-NP loaded with siRNA demonstrated selective intratumoral delivery in ovarian cancer models.
- Targeted silencing of growth-promoting genes (POSTN, FAK, PLXDC1) and therapeutic efficacy were observed.
- In vivo tumor vascular targeting and significant tumor growth inhibition were achieved by delivering PLXDC1-targeted siRNA.
Conclusions:
- RGD-CH-NP serves as a novel and highly selective delivery system for siRNA.
- This system shows potential for broad applications in treating various human diseases.
- The targeted approach offers a promising strategy for cancer therapy.
Related Concept Videos
02:15Experimental RNAi
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
02:30siRNA - Small Interfering RNAs
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
01:23RNA Interference
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...